search icon
  • Print
  • ShareThis
  • Text Size


In order to add a post to the discussion forum you need to be an IDSA member. If you are an IDSA member, please login now. Please read our Discussion Forum Guidelines and Terms of Use before joining.

Hepatitis C

Welcome to Hepatitis C Management Discussion Board! The Hepatitis C Management Discussion Board provides Infectious Disease Clinicians a platform to connect with colleagues to exchange information, case studies, complications, and new developments on matters concerning hepatitis C treatment and management. Certain case studies will be developed into clinical vignettes and will be available to Infectious Disease Clinicians for future reference. Please be respectful of all participants and their respective comments. Please read our Terms of Use and Discussion Forum Guidelines.

 

Any diagnostic or therapeutic recommendations and all opinions presented are those of the individual contributor. They do not necessarily represent the views of IDSA. The reader assumes all risks in using this information. The IDSA Hepatitis C Discussion Forum is in full compliance with HIPPA. IDSA bears no responsibility for the accuracy of participant comments and will bear no legal liability for discussion results.

If a participant wishes to post an issue on the IDSA Hepatitis C Discussion Forum, the participant is strongly urged to provide contact information for possible offline discussion via phone or email concerning the posted issue.


RSS Feed Print Category View
AbbVie Submits FDA Application for All Oral HCV Therapy
tkim@idsociety.org
Posted: Tuesday, April 22, 2014 1:52 PM
Joined: 2/20/2013
Posts: 40


"AbbVie has submitted an FDA application for its promising all-oral hepatitis C treatment, expecting approval this year as it prepares for a three-way race with perceived leaders Gilead Sciences and Merck.

The drug, a combination of three antiviral agents, is part of a new class of highly effective hep C treatments that eschew shots and work without interferon, a painful adjunct to standard therapy that keeps some patients at bay. Across 6 Phase III studies in more than 2,300 patients with the tough-to-treat genotype 1 hep C, AbbVie's therapy charted impressive 12-week cure rates, notching a 99% sustained virologic response mark in some populations. The company's FDA filing falls right in line with its previously disclosed schedule, and AbbVie has said it plans to launch the cocktail therapy later this year.

That should put it right behind Gilead, which in February filed an application for a combo of its own that pairs the blockbuster antiviral Sovaldi with an NS5A inhibitor called ledipasvir."

To read more, please visit:  http://www.fiercebiotech.com/story/abbvie-heads-fda-its-hep-c-combo-race-gilead-merck/2014-04-22#ixzz2zdfEUlIv 


 

| HIVMA | Contact Us

© Copyright IDSA 2014 Infectious Diseases Society of America

Full Site Mobile Site